Berg P A, Klein R
Medizinische Klinik Abt. II, Universität Tübingen.
Praxis (Bern 1994). 2002 Aug 21;91(34):1339-46. doi: 10.1024/0369-8394.91.34.1339.
Autoimmune hepatitis (AIH) is a rare autoimmune disease (incidence about 5% among all chronic liver disorders) that reflects a loss of tolerance to normal hepatic proteins. AIH is characterized by female preponderance, hypergammaglobulinemia, extrahepatic syndromes and a good response to immunosuppressive treatment. AIH may be subdivided into two or three subtypes. AIH type 1 is characterized by antinuclear autoantibodies (ANA) and/or smooth muscle antibodies (SMA). SMA are actin-specific, can occur without ANA and their presence relates strongly to AIH. AIH type 2 is defined by the presence of anti-liver-kidney microsomal antibodies (LKM-1). Patients with AIH type 2 are typically younger at the time of disease onset, exhibit higher inflammatory activity, suffer more frequent relapses under immunosuppressive treatment and are more likely to progress to cirrhosis. AIH type 3 is characterized by autoantibodies against the soluble liver antigen (SLA) and liver-pancreas antigen (LP), but ANA/SMA are frequently present and, therefore, some authors consider this autoantibody manifestation as belonging to AIH type 1. Antineutrophil cytoplasmic antibodies (ANCA) recognize cytoplasmic or nuclear components of neutrophilic granulocytes and are detected with high prevalence in patients with autoimmune liver diseases. They are associated with AIH type 1 but not with AIH type 2. However, 40-70% of patients with primary sclerosing cholangitis (PSC) also produce these autoantibodies. Autoimmune cholangitis is an idiopathic disorder with mixed hepatocellular and cholestatic findings that typically has antinuclear antibodies (ANA). It may be considered as an atypical form of primary biliary cirrhosis. It has been recognized that some forms of AIH may also occur with variable incidence and severity especially in patients with primary biliary cirrhosis (overlap AIH/PBC) or primary sclerosing cholangitis (AIH/PSC). On the basis of clinical, biochemical, serological, histological and radiological criteria a clear distinction between these conditions can be readily made in the majority of cases. An association of AIH-typical autoantibodies (anti-LKM-1, anti-SLA/LP) in association with antimitochondrial autoantibodies (AMA) almost confirm the overlap syndrome AIH/PBC. In PSC patients expressing typical ERCP findings and suffering from inflammatory bowel disease (IBD), the diagnosis of an overlap syndrome between PSC/AIH can be readily made in the presence of ANCA and AIH relevant autoantibodies. Apart from this kind of overlap syndrome involving different types of autoimmune disorders within the liver AIH can be also associated with other organspecific autoimmune disorders as documented in the autoimmune polyglandular syndrome type 1 (APS-1). In this disease homozygosity for a defect in a single gene (AIRE) leads to a broad spectrum of organ specific autoimmune diseases.
自身免疫性肝炎(AIH)是一种罕见的自身免疫性疾病(在所有慢性肝病中发病率约为5%),反映了对正常肝脏蛋白的免疫耐受丧失。AIH的特征为女性居多、高球蛋白血症、肝外综合征以及对免疫抑制治疗反应良好。AIH可分为两个或三个亚型。1型AIH的特征是存在抗核自身抗体(ANA)和/或平滑肌抗体(SMA)。SMA具有肌动蛋白特异性,可在无ANA的情况下出现,其存在与AIH密切相关。2型AIH由抗肝肾微粒体抗体(LKM-1)的存在所定义。2型AIH患者通常在疾病发作时年龄较小,炎症活动度较高,在免疫抑制治疗下复发更频繁,且更易进展为肝硬化。3型AIH的特征是存在针对可溶性肝抗原(SLA)和肝胰抗原(LP)的自身抗体,但ANA/SMA也常出现,因此一些作者认为这种自身抗体表现属于1型AIH。抗中性粒细胞胞浆抗体(ANCA)识别嗜中性粒细胞的胞浆或核成分,在自身免疫性肝病患者中检测到的频率较高。它们与1型AIH相关,但与2型AIH无关。然而,40%-70%的原发性硬化性胆管炎(PSC)患者也会产生这些自身抗体。自身免疫性胆管炎是一种特发性疾病,具有肝细胞和胆汁淤积混合表现,通常有抗核抗体(ANA)。它可被视为原发性胆汁性肝硬化的一种非典型形式。已经认识到,某些形式的AIH也可能以不同的发病率和严重程度出现,尤其是在原发性胆汁性肝硬化(重叠AIH/PBC)或原发性硬化性胆管炎(AIH/PSC)患者中。根据临床、生化、血清学、组织学和放射学标准,在大多数情况下可以很容易地明确区分这些情况。AIH典型自身抗体(抗LKM-1、抗SLA/LP)与抗线粒体自身抗体(AMA)同时存在几乎可确诊重叠综合征AIH/PBC。在表现出典型内镜逆行胰胆管造影(ERCP)结果且患有炎症性肠病(IBD)的PSC患者中,在存在ANCA和与AIH相关的自身抗体时,可很容易地诊断出PSC/AIH重叠综合征。除了这种涉及肝脏内不同类型自身免疫性疾病的重叠综合征外,AIH还可与其他器官特异性自身免疫性疾病相关,如在1型自身免疫性多腺体综合征(APS-1)中所记载的那样。在这种疾病中,单个基因(AIRE)缺陷的纯合子会导致广泛的器官特异性自身免疫性疾病。